

*Study of CD123 (Interleukin-3 receptor alpha chain)
and NF- κ B (Nuclear factor kappa B) in Adult Acute
Myeloid Leukemia Patients*

Thesis

*Submitted for partial fulfilment of the M.D degree in
Clinical Haematology*

By

Dr.Hani Salman Hassan Ayyash

M.B.B.Ch, M.sc

Under Supervision of

Professor Dr. Inas Ahmed Asfour

*Professor of Internal Medicine and Clinical Haematology
Faculty of Medicine, Ain Shams University*

Dr. Soha Raouf Youssef

*Professor of Clinical Pathology
Faculty of Medicine, Ain Shams University*

Dr.Maryse Soliman Ayoub

*Assistant Professor of Internal Medicine and Clinical Haematology
Faculty of Medicine, Ain Shams University*


Dr.Nevine Nabil Moustafa

*Assistant Professor of Internal Medicine and Clinical Haematology
Faculty of Medicine, Ain Shams University*

Dr.Ghada Metwally El-Gohary

*Assistant Professor of Internal Medicine and Clinical Haematology
Faculty of Medicine, Ain Shams University*

Faculty of Medicine
Ain Shams University
2008



Acknowledgement

♦ *I would like to express my deepest gratitude and gratefulness to **Prof. Dr. Inas Ahmed Asfour** Professor of Clinical Hematology & Internal Medicine, Faculty of Medicine, Ain Shams University, for her kind support , continuous encouragement and precious help to accomplish my research.*

♦ *I am deeply indebted to **Prof. Dr. Soha Raouf Youssef**, Professor of Clinical Pathology,, Faculty of Medicine, Ain Shams University, for her kind work and valuable scientific advice.*

♦ *My deepest gratitude and gratefulness to **.Dr. Maryse Soliman Ayoub** Assistant Professor of Clinical Hematology & Internal Medicine, Faculty of Medicine, Ain Shams University, for her kind trust ,meticulous and noble supervision, to accomplish my research.*

♦ *My thanks to **Dr. Nevine Nabil Moustafa** , Assistant Professor of Clinical Hematology & Internal Medicine, Faculty of Medicine, Ain Shams University, for her kind help and care.*

♦ *My thanks to **Dr. Dr. Ghada Metwally El-Gohary** ,Assistant Professor of Clinical Hematology & Internal Medicine, Faculty of Medicine, Ain Shams University, for her kind help and care.*


Genuine appreciation to my teachers, my family, colleagues& friends for their continuous support.

*Dr.Hani Salman Ayyash
Cairo-2011*

List of contents

Title	Page nr.
Introduction	I
Aim of The Work	III
List of Tables	IV
List of Figures	VI
List of Abbreviations	VIII
Chapter 1:Acute Myeloid Leukemia	1
I.Introduction	1
II.Epidemiology of the disease	1
III.Pathophysiology of the disease:	2
III.1.Leukemogenesis	3
III.2.Resistence to apoptosis	7
III.3.Signal Transduction	13
III.4.Microenviroment	16
IV.Diagnosis of AML	16
IV.1.Symptoms	16
IV.2.Physical Examination	17
IV.3.Laboratory Studies	18
IV.4.Classification of AML	23
IV.5.Immunophenotyping of AML Cells	25
IV.6.Cytogenetics in AML	27
V.Prognostic factors in AML	24
VI.Therapy of AML	32
VI.1. Treatment of adult patients with AML	32
VI.1.a.Induction Therapy	34
VI.1.b.Post-remission Therapy	39
VI.1.c.Primary refractory disease	43
VI.1.d. Maintenance Therapy	44
VI.1.e. Novel Agents in AML	44
VI.1.f.Targeting the LSC by altered cholesterol metabolism	50
VI.1.g. Immunotherapy & Radioimmunotherapy	51
VI.1.h.Relapsed and Refractory AML	56
VI.2. AML in Older Patients	60
VI.2.a.Patients age 60 to 74	61
VI.2.b.Patients age 75 or older	64
VI.2.c.Future directions in older AML	65
VI.3.Acute Myeloid Leukemia in Pregnancy	65

Acute Promyelocytic Leukemia	67
Haematopoietic Stem Cell Transplantation	72
Cord Blood Transplantation	79
Complications & Related Toxicities of HSCT	85
Chapter 2: Interleukin-3 receptor alpha chain (CD123)	100
I. Introduction	100
II. Basic background & biological implication of IL-3	103
III. IL-3R α expression in AML	107
IV. IL-3R α & Therapy	108
Chapter 3: Nuclear factor kappa B (NF-κB)	114
I. Introduction	114
II. Basic background of NF- κ B	115
III. Role of NF- κ B in Survival & Apoptosis	119
IV. Role of NF- κ B in Leucomogenesis	121
V. Targeted Therapy in AML via NF- κ B	125
Chapter 4: Patients & Methods	138
I. Assessment of CD123	141
II. Quantitative assay of NF- κ B in BM using ELISA	143
III. Statistical analysis	149
Chapter 5: Results	150
I. Patient's data	150
II. Comparative statistics	169
III. Correlation statistics	190
IV. The ROC curves	199
V. Survival	202
Chapter 6: Discussion	204
Chapter 7: Summary	221
Chapter 8: Conclusions	224
Chapter 9 : Recommendations	226
Chapter 10: References	227
Chapter 11: Arabic Summary	264



Introduction

Acute myeloid leukemia (AML) is a genetically heterogeneous clonal disorder characterized by the accumulation of acquired somatic genetic alterations in hematopoietic progenitor cells that alter normal mechanisms of self-renewal, proliferation and differentiation. **(Dohner & Dohner ; 2008)**

The genomic alterations in AML affect the function of signaling molecules, transcription factors, and growth-factor receptors and also determine the phenotype of the leukemia and influence the response to treatment. Moreover, the multiplicity of genomic changes that frequently coexist in a single leukemic cell reflects the successive transforming events that accumulate in the leukemic clone during the development of AML. **(Löwenberg, 2008)**

While a stem cell origin for myeloid leukemia has been postulated for over three decades, definitive experimental evidence for leukemia stem cells (LSC) has only been generated in recent years. These studies have demonstrated the central role of LSC in myeloid leukemia and highlighted the critical need for therapeutic strategies that directly target the LSC population. **(Gary et al., 2004)**

In AML , LSCs are phenotypically defined as CD34+, CD38-, CD71-, CD90-, HLA-DR-, CD117-, and CD123+. Even though most of these antigenic features are shared with normal hematopoietic stem cells(HSCs) (CD34+, CD38-, CD71-, and HLA-DR-), at least three markers have been found to be unique to LSCs (CD90-, CD117-, and CD123+) . **(Guzman & Jordan, 2004).**

Interleukin-3 receptor alpha chain (CD123) is over expressed in about 45% of acute myeloid leukemia's , this phenomenon was associated with high blast cell counts at diagnosis, high rate of cycling of leukemic blasts and with a worse prognosis. **(Riccocini et al., 2004)**

The mechanisms underlying the elevated CD123 expression observed in AML blasts are unclear. The increased CD123 expression observed in AML could be mainly related to a transcriptional mechanism, as suggested by the observation that increased levels of CD123 mRNA are observed in most patients exhibiting high CD123 levels. **(Testa et al., 2005)**

The transcription nuclear factor kappa B (NF- κ B) can intervene in oncogenesis through its capacity to regulate the expression of a large number of genes that regulate apoptosis, cell proliferation and differentiation as well as inflammation, angiogenesis and tumor migration. **(Cilloni et al., 2007)**

Constitutive or aberrant activation of NF- κ B is frequently encountered in many human tumors as well as hematological malignancies including acute myeloid leukemia and is associated with a resistant phenotype and poor prognosis. In AML the mechanism of such persistent NF- κ B activation is not clear but may involve defects in signaling pathways, mutations, or chromosomal rearrangements. Suppression of constitutive NF- κ B activation inhibits the oncogenic potential of transformed LSC and thus makes NF- κ B an interesting new therapeutic target **(Sethi et al., 2008)**

Aim of the work

- To assess the relationship between CD123 (Interleukin-3 receptor alpha) expression as a marker for acute myeloid leukemia , and Nuclear factor – kappa B(NF- κ B) level, in adult patients with acute myeloid leukemia at presentation & after induction therapy.
- To find out the possible correlation of each of the two parameters to the current known diagnostic and prognostic factors in AML .
- To be translated therapeutically as a targeted therapy for AML.

List of Tables

Table	Title	Page nr.
Table 1	Test/procedures in the initial work-up of a patient with AML	22
Table 2	French-American-British (FAB) Classification of AML	23
Table 3	Acute myeloid leukaemias (AML) according to WHO Classification * New entities incorporated	24-25
Table 4	Immunophenotyping of AML cells	26
Table 5	Expression of cell-surface and cytoplasmic markers for the diagnosis of AML and mixed phenotype acute leukemia	26-27
Table 6	Standardized reporting for correlation of cytogenetic and molecular genetic data in AML with clinical data .	27
Table 7	Biological and clinical features associated with gene mutations in acute myeloid leukemia	28-29
Table 8	Different prognostic factors	31-32
Table 9	Novel Agents in Acute Myeloid Leukemia	53-56
Table 10	Targets for anti-leukemic stem cells therapies	55-56
Table 11	Response criteria in AML	57-58
Table 12	Prognostic index for younger adults with AML in relapse	59
Table 13	Morphologic Subtypes of Acute Promyelocytic Leukemia	67
Table 14	Acute Promyelocytic Leukemia: Chromosomal Translocations and Fusion Products	68
Table 15	Indications for Allo-HSCT among young adults with AML in CR1	75
Table 16	Summary of reported conditioning regimens in CBT	80-81
Table 17	Recommended Staging and Grading of Acute Graft Versus Host Disease (GVHD)	87-88
Table 18	Health problems in long-term survivors after BMT	92
Table 19	NF- κ B family members	116
Table 20	Demographic and clinical data of the studied patients at diagnosis	150
Table 21	Induction chemotherapy offered to patients at diagnosis (n.40)	152
Table 22	Laboratory data of the studied patients at diagnosis (n.= 40)	154
Table 23	Echocardiography findings in studied patients	155
Table 24	Flow cytometry for studied patients at diagnosis (n.= 40)	156
Table 25	FAB classification of patients at presentations (n.= 40)	156
Table 26	Patients risk groups according to cytogenetic analysis (n.= 40)	157
Table 27	Molecular pattern in Unfavourable group (n.= 12)	158
Table 28	Molecular pattern in favourable group (n.= 19)	158
Table 29	Descriptive data of the studied patients at follow up (nr.= 20)	160
Table 30	FAB classification of surviving patients (n.= 20)	160
Table 31	FAB classification of remitted patients (n.= 12)	161
Table 32	Molecular pattern in remitted patients (n.= 12)	161
Table 33	FAB classification of resistant patients (n.= 8)	162
Table 34	Molecular pattern in resistant patients (n.= 8)	162

Table 35	Complications during therapy in studied patients at diagnosis	164
Table 36	Different therapies for patients during complications	165
Table 37	Descriptive data of CD123 and NF- κ B values for studied patients at diagnosis (n.= 40)	166
Table 38	Descriptive data of CD123 and NF- κ B values for surviving patients at D28 (n.=20)	166
Table 39	Diagnosis of control subjects (n.= 20)	167
Table 40	Laboratory data of the control subjects (n.= 20)	168
Table 41	Descriptive data of CD123 and NF- κ B values for control group (n=20)	168
Table 42	Comparison between control group versus all patients at diagnosis	170
Table 43	Comparison between control group versus all patients at follow up	171
Table 44	Comparison between all patients at diagnosis & at follow-up	173
Table 45	Comparison between group of remitted patients with group of non-remitted patients at diagnosis (n.= 40)	174
Table 46	Comparison between values at diagnosis to values at follow up among remitted patients' group	176
Table 47	Comparison between resistant patients at diagnosis and at follow-up	177
Table 48	Comparison between remitted versus resistant patients at diagnosis (n.=20)	179
Table 49	Comparison between remitted versus resistant patients at follow-up	180
Table 50	Comparison between FAB subtypes at diagnosis	182
Table 51	Comparison between cytogenetic subtypes' at diagnosis	183
Table 52	Comparison between alive and dead patients at diagnosis	185
Table 53	Comparison between alive patients at diagnosis and at follow-up	186
Table 54	Correlation of CD123 and NF- κ B markers at diagnosis with laboratory parameters	190
Table 55	Correlation of CD123 and NF- κ B markers at diagnosis with immunophenotype parameters	192
Table 56	Correlation of CD123 and NF- κ B markers at follow-up with laboratory parameters	194
Table 57	Correlation of CD123 and NF- κ B markers at follow up with immunophenotype parameters	196
Table 58	Parameters of CD123 for ROC curve	199
Table 59	Parameters of NF- κ B for ROC curve	201
Table 60	Parameters of Overall survival	202

List of Figures

Figure	Title	Page nr.
Figure 1	Models of stem cell leukemogenesis	4
Figure 2	Overview of normal HSCs and LSCs	5
Figure 3	Diagram of Cell Cycle Control	6
Figure 4	Diagram of oncogene and proto-oncogene	6
Figure 5	Models for leukemia development and therapeutic targets	8
Figure 6	Bcl & Bax	9
Figure 7	Model for LSC apoptosis	10
Figure 8	Comparison of LSC and leukemic cells	11
Figure 9	Diagram of apoptosis	12
Figure 10	Oncogenic functions of mutant p53 proteins	12
Figure 11	Tyrosine signal kinas pathways	14
Figure 12	Inactive tyrosine kinase receptor system	14
Figure 13	Overview of signal transduction pathways involved in apoptosis	
Figure 14	Pie chart illustrating the molecular heterogeneity of cytogenetically normal AML based on mutations in the NPM1, CEBPA, MLL, FLT3(ITD and TKD mutations at codons D835and I836), NRAS, and WT1 genes	30
Figure 15	Role of P27 in cell cycle	50
Figure 16	Algorithm for donor selection and conditioning regimen	83
Figure 17	Comparison of LSC and leukemic cells	101
Figure 18	Targeting the AML-LSC	112
Figure 19	Schematic diagram of NF- κ B protein structure	117
Figure 20	Mechanism of NF- κ B action	118
Figure 21	NF- κ B & I κ B	120
Figure 22	Mechanisms of Constitutive activation of NF- κ B	124
Figure 23	Potential use of leukemia stem cell (LSC)-targeted agents	124
Figure 24	Materials and curve of the study	148
Figure 25	Cultures patterns in feverish patients	151
Figure 26	Source of fever at presentation	151
Figure 27	Induction chemotherapy offered to patients at diagnosis	153
Figure 28	Echocardiography findings in studied patients	155
Figure 29	Flow cytometry in studied patients	156
Figure 30	FAB classification of studied patients at presentation	157
Figure 31	Patients risk groups according to cytogenetic analysis	158
Figure 32	Molecular pattern in unfavourable group	158
Figure 33	Molecular pattern in favourable group	159
Figure 34	BM evaluation at D28 after induction therapy	160
Figure 35	FAB classification of the survived patients	161
Figure 36	FAB classification of the remitted patients	161
Figure 37	Molecular patterns in remitted patients	162
Figure 38	FAB classification of the resistant patients	162
Figure 39	Molecular patterns in resistant patients	163
Figure 40	Management of the non-remitted patients	163
Figure 41	Complications during follow up	164
Figure 42	Therapies for patients during complications	165
Figure 43	Diagnosis of the control subjects	167

Figure 44	Comparison between control group versus all patients at diagnosis	170
Figure 45	Comparison between control group versus all patients at follow up	172
Figure 46	Comparison between all patients at diagnosis and at follow-up	173
Figure 47	Comparison between group of remitted patients with group of non-remitted patients at diagnosis (n.= 40)	175
Figure 48	Comparison between values at diagnosis to values at follow up among remitted patients' group	176
Figure 49	Comparison between resistant patients at diagnosis and at follow-up	178
Figure 50	Comparison between remitted versus resistant patients at diagnosis	179
Figure 51	Comparison between remitted versus resistant patients at follow-up	181
Figure 52	Comparison between FAB subtypes at diagnosis	182
Figure 53	Comparison between cytogenetic subtypes' at diagnosis	184
Figure 54	Comparison between alive and dead patients at diagnosis	185
Figure 55	Comparison between alive patients at diagnosis and at follow up	186
Figure 56	Shows Comparison of CD123 with all studied subjects	187
Figure 57	Shows Comparison of NF-κB Plasma with all studied subjects	187
Figure 58	Shows Comparison of NF-κB Cytoplasmic with all studied subjects	188
Figure 59	Shows Comparison of NF-κB Nuclear with all studied subjects	188
Figure 60	Shows Comparison of NF-κB C/N Ratio with all studied subjects	189
Figure 61	Shows a significant positive correlation exists between Age and NF-κB Nuclear fraction level	191
Figure 62	highly significant positive correlation between BM Blasts and NF-κB nuclear fraction level	195
Figure 63	Highly positive significant correlation exists between NF-κB Plasma & CD123 level	197
Figure 64	Positive significant correlation exists between NF-κB Ratio & NF- κB Cytoplasmic fraction level	197
Figure 65	Highly positive significant correlation exists between NF-κB Nuclear fraction & NF- κB Cytoplasmic fraction level	198
Figure 66	Shows ROC curves for CD123 at Diagnosis & at follow-up	199
Figure 67	Shows ROC curves for NF-κB parameters at follow-up	201
Figure 68	Overall survivals diagrams for CD123 & NF-κB parameters	203

List of Abbreviations

AA	aplastic anemia
AB	antibiotics
ABCB1	ATP-binding cassette sub-family b member 1
ABCG	ATP-binding cassette sub-family G member
ABL1	Abelson murine leukemia viral oncogene homolog 1
ACD	anemia of chronic disease
AHD	antecedent hematological disorder
AKT	murine thymoma viral oncogene
ALL	acute lymphoblastic leukemia
alloHSCT	allogeneic hematopoietic stem cell transplantation
ALFA	Acute Leukemia French Association
AML	acute myeloid leukemia
AMLCG	acute myeloid leukemia cooperative german group
AML-ETO	acute myeloid leukemia- eto (RUNX1) gene
ANCs	absolute neutrophil counts
APL	acute promyelocytic leukemia
aPTT	activated partial thromboplastin time
ARDS	acute respiratory distress syndrome
Ara-C	cytarabine
Ara-CTP	arabinosylcytosine triphosphate
autoHSCT	autologous hematopoietic stem cell transplantation
ATRA	all-trans retinoic acid
ATG	anti-thymocyte globulin
ATO	arsenic trioxide
AV	arterio-ventricle
AUC	area under the curve
AVN	avascular necrosis
BAALC	brain and acute leukemia cytoplasmic gene
BAD	bcl-2-associated death promoter
BAFF	B cell activating factor receptor
βc	beta common chain
BCL-2	b-cell lymphoma 2
BCR-Abl	breakpoint cluster region-abelson murine leukemia viral oncogene
BCRP	b cell receptor prorien
Bcl-X_L	b-cell lymphoma-extra large
Bfla/A1	Bcl-2 related gene , anti-apoptotic
BM	bone marrow
Bmi-1	polycomb ring finger oncogene 1
BMT	bone marrow transplantation
BU	busulfan
BUN	blood urea nitrogen
c	cytoplasm
c-Able	cytoplasm of abelson murine leukemia viral oncogene
CALGB	cancer and leukemia group b
CB	cord blood
CBC	complete blood cell

CBF	core binding factor
CBFB	core-binding factor subunit beta
CBT	cord blood transplantation
CCAAT	cytidine-cytidine-adenosine-adenosine-thymidine
CD	cluster differentiation
CEBPA	CCAAT/enhancer-binding protein alpha
Chest infec.	chest infection
CIBMTR	center for international blood and marrow transplant research
CLL	chronic lymphocytic leukemia
c-KIT	cytokine kinase tyrosine receptor
CLL-1	c-type lectin-like molecule-1
CML	chronic myeloid leukemia
c-MPO	cytoplasmic myeloperoxidase
Myc	myelocytomatosis viral oncogene homolog
CML	chronic myeloid leukemia
CMV IgM/G	cytomegalovirus immunoglobulin
C/N	cytoplasmic nuclear ratio
CN-AML	cytogenetically normal acute myeloid leukemia
CNS	central nervous system
CR	complete remission
CR1	complete response to initial therapy
CRi	complete remission with incomplete recovery
CRp	complete responses with incomplete platelet recovery
Rel	proto-oncogene protein is a protein that is encoded by the <i>REL</i> gene
CSC	cancer stem cell
CSF	cerebrospinal fluid
CT	computed tomography
CXCR4	chemokine receptor
CXR	chest x-ray
DA	diagnostic accuracy
DAPT	difluorophenacetyl-l-alanyl-S-phenylglycine t-butyl ester
DEK	oncogene (DNA binding)
Del	deletion
DFS	disease free survival
DLI	donor leukocyte infusions
DIC	disseminated intravascular coagulation
DMAPT	dimethyl amino parthenolide
DNA	deoxyribonucleic acid
DNMT	DNA methyltransferase
DNR	daunorubicin
d.t	due to
DT	diphtheria toxin
DW	dextrose water
EBMT	european bone marrow transplant
EBV	Epstein-Barr virus
ECG	electrocardiogram
ECOG	eastern cooperative oncology group
ECHO	echo-cardiography

EDTA	ethylene Diamine Tetra Acetic acid
EGFR	epidermal growth factor receptor
ELAM-1	endothelial leukocyte adhesion molecule
ELISA	enzyme-linked immunosorbent assay
EMEA	european medicine agency
EORTC	european organization for research and treatment of cancer
EPICS	experimental physics and industrial control system
ERG	v-ets avian erythroblastosis virus E26 oncogene-like
ERK	extracellular signal-regulated kinases
ESR	erythrocyte sedimentation rate
ETO	eight-twenty-one
EVII	ecotropic viral integration site 1 gene
FAB	french-american-british
FCM	flow cytometry
FDA	food and drug administration
FDPs	fibrin degradation products
FISH	fluorescence in situ hybridization
FLAG	fludarabine + high dose ara-c + G-CSF
FLIP	FLICE inhibitory protein
FLT3	fms-like tyrosine kinase 3
FN	false negative
FP	false positive
FSH	follicle-stimulating hormone
G+ ve	gram positive
G- ve	gram negative
g/dl	gram per deciliter
g/L	gram per liter
GADD	apoptosis- and DNA damage-inducible gene.
G-CSF	granulocyte colony stimulating factor
GFR	glomerular filtration rate
GIMEMA	gruppo italiano malattie ematologiche d'adulto
GO	Gemtuzumab ozogamicin
GM-CSF	granulocyte macrophage colony stimulating factor
GM-CSFR	granulocyte macrophage colony stimulating factor receptor
GRb2	growth factor receptor-bound protein 2
GVHD	graft-versus-host disease
GVL	graft-versus-leukemia
HA	hemolytic anemia
Hb	hemoglobin
HBV	hepatitis B virus
HBsAg	hepatitis B surface antigen
HCL	hydrogen chloride
HCV	hepatitis C virus
HCV Ab	hepatitis C virus antibody
HDAC	Histone deacetylase
HEPA	high-efficiency particulate air
HER2	human epidermal growth factor receptor 2
HGFs	hemopoietic growth factors
HHC-8	human herpes virus